Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 with Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
NCT06789679Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tegafur in pancreatic ductal adenocarcinoma (PDAC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jan 2025; status: recruiting.
02
Drugs
tegafur
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06789679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06789679.